Showing results (571-580 of 667) with videos related to

Sort By:
Pageof 67
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyEric Raymond, Alba A Brandes, Christian Dittrich, et al.
The Journal of Biological Chemistry|January 1, 2004
Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cellsStephan Kiessling, Gerhard Muller-Newen, Sandra N Leeb, et al.
The EMBO Journal|September 28, 2001
A completely foreign receptor can mediate an interferon-gamma-like responseB Strobl, V Arulampalam, H Is'harc, et al.
Future Oncology (London, England)|September 4, 2024
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutationsSuzanne George, Jean-Yves Blay, Ping Chi, et al.
High Altitude Medicine & Biology|December 10, 2024
The Effects of Nocturnal Hypoxemia on Cognitive Performance in Andean HighlandersElizabeth V Young, Matea A Djokic, Erica C Heinrich, et al.
The Journal of Pathology|May 28, 2005
The gene expression profile of extraskeletal myxoid chondrosarcomaSubbaya Subramanian, Robert B West, Robert J Marinelli, et al.
Blood|February 7, 1998
DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint functionM C Heinrich, M E Hoatlin, A J Zigler, et al.
Frontiers in Physiology|May 22, 2020
Relationships Between Chemoreflex Responses, Sleep Quality, and Hematocrit in Andean Men and WomenErica C Heinrich, Jeremy E Orr, Dillon Gilbertson, et al.
JCI Insight|December 15, 2020
Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatmentShuai Ye, Dinara Sharipova, Marya Kozinova, et al.
The American Journal of Pathology|June 25, 2004
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation statusRobert B West, Christopher L Corless, Xin Chen, et al.
Pageof 67